Chinese inhibitor drug candidate becomes first to enter phase
Chinese biotech company Jacobio Pharma announced on Monday that it had received approval from Chinese regulatory authorities for the registration phase-3 clinical trial of a combination therapy using its SHP2 inhibitor drug candidate JAB-3312.
SHP2 inhibitors are expected worldwide to have a substantial clinical effect in cancer and immunity disease treatment, and the approval made JAB-3312 the first SHP2 inhibitor to enter the phase-3 clinical study globally.
The approved clinical study in China is designed to evaluate the efficacy and safety of JAB-3312 in combination with the company's other investigational drug candidate KRAS G12C inhibitor glecirasib, for treating first-line non-small cell lung cancer patients with KRAS G12C mutations.
The control arm is the current standard treatment for first-line non-small cell lung cancer, which is the combination therapy of PD-1 antibody and chemotherapy.
Related articles
Billie Eilish announces 'Hit Me Hard and Soft' arena world tour
NEW YORK (AP) — Billie Eilish is hitting the road.The pop performer will embark on a worldwide arena2024-04-30China clocks world's 2nd best time in men's 4x100m medley relay victory at Hangzhou Asiad
(Xinhua) 14:06, September 27, 2023Xu Jiayu, Qin Haiyang, Wang Changhao and Pan Zhanle (L to R) of Ch2024-04-30Promoting Family Education, Raising Happy Children
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-04-30Telling China's Story in Objective, Comprehensive Way
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-04-30A third of foreign students seeking to stay in the UK are at just SIX institutions, figures show
More than a third of foreign students who went on to claim asylum in Britain were sponsored to come2024-04-30- Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-04-30
atest comment